Supplemental material
Expert Opinion on Drug Safety
Volume 21, 2022 - Issue 10
Open access
5,541
Views
5
CrossRef citations to date
0
Altmetric
Original Research
Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study
Kohei Kakua Department of Medicine, Kawasaki Medical School, Okayama, Japanhttps://orcid.org/0000-0003-1574-0565View further author information
, Kazuhiro Yamamotob Department of Cardiovascular Medicine, and Endocrinology and Metabolism, Faculty of Medicine, Tottori University, Tottori, Japanhttps://orcid.org/0000-0003-2766-4213View further author information
, Yumiko Fukushimac Medicine Division, Nippon Boehringer Ingelheim Co. Ltd, Tokyo, JapanView further author information
, Hristo Llievd Global Pharmacovigilance, Boehringer Ingelheim Pharma GmbH & Co. Kg, Ingelheim, GermanyView further author information
& Atsutaka Yasuic Medicine Division, Nippon Boehringer Ingelheim Co. Ltd, Tokyo, JapanCorrespondence[email protected]
https://orcid.org/0000-0003-4903-7210View further author information
https://orcid.org/0000-0003-4903-7210View further author information
Pages 1315-1328
|
Received 16 Feb 2022, Accepted 15 Mar 2022, Published online: 30 Mar 2022
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.